Jefferies Starts Collegium Pharmaceutical (COLL) at Buy

Jefferies initiates coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Buy rating and a price target of $20.00.

Analyst David Steinberg commented, "Collegium (COLL) is an emerging leader in abuse-deterrent extended-release (ER) opioids used for treating chronic pain. COLL is on the cusp of commercializing Xtampza (oxycodone ER; Oct 12 FDA action date) – a potentially improved and safer alternative to Purdue’s $2.5B market-leader OxyContin. The co also has a lower risk R&D pipeline based on its DETERx abuse-deterrent platform, with four drugs in development."

For an analyst ratings summary and ratings history on Collegium Pharmaceutical click here. For more ratings news on Collegium Pharmaceutical click here.

Shares of Collegium Pharmaceutical closed at $17.00 yesterday.

You May Also Be Interested In

• Cummins (CMI) PT Lowered to $675 at Jefferies
• Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
• Viking Holdings (VIK) PT Raised to $82 at Mizuho